Hillstream BioPharma Acquires Key Assets to Portfolio Including QUATRAMER Drug Delivery Technology Platform and Key Immuno-Oncology Compounds

Acquisition Positions Hillstream as a Diversified Biotechnology Company Developing Novel, IND-Ready
Immuno-Oncology Treatments for Orphan Tumors with Devastating and Unmet Need

Chester, NJ — September 10, 2019 – Hillstream BioPharma Inc. (“Hillstream”) today announced the acquisition of key immuno-oncology (IO) assets from privately held NanoProteagen, Inc., including its proprietary drug delivery platform QUATRAMER, a proprietary, non-viral tumor infiltrating enhanced injectable suspension.

The company believes this acquisition solidifies its position as a novel drug delivery platform company, as it includes several immuno-oncology drug candidates.  In addition to the QUATRAMER delivery platform, which forms the basis of the entire portfolio, Hillstream has acquired and is developing HSB-114, an immunotherapeutic agent delivering the human tumor necrosis factor-alpha (TNF-α) gene.  Hillstream is progressing towards a rapid IND filing process and plans to initiate a clinical trial in advanced, metastatic soft tissue sarcomas (STS).

“With the addition of QUATRAMER as our key platform, we are now poised to enter the IO space with a novel technology that we believe may provide a non-viral tumor specific delivery vehicle of cytokines with high efficacy in tumors with too narrow a therapeutic index for clinical feasibility, including TNF-alpha and others,” stated Randy Milby, chief executive officer of Hillstream. “With the preclinical success we’ve had to date with HSB-114, we anticipate a rapid progression toward an IND and initiation of Phase 1b/2a trials.  We look forward to sharing our progress of these and future milestones with current and potential shareholders.” (more…)


Hillstream BioPharma Announces Participation at the 2019 ASCO Annual Meeting, May 31-June 4, 2019, McCormick Place, Chicago, IL

Chester, N.J., May 20, 2019 – Hillstream BioPharma Inc. (“Hillstream”), a development-stage company advancing improved therapies for patients with cancer, today announced it intends to have a presence at the 2019 ASCO Annual Meeting, May 31-June 4, 2019 at McCormick Place, Chicago, IL.

Event:      2019 ASCO Annual Meeting
Date:        Friday, May 31, 2019 – Tuesday, June 4, 2019
Time:        8:00am – 6:00pm CDT
Location:  McCormick Place, Chicago, IL (more…)


Interview with Randy Milby, CEO

This is the second post in an interview series with CEOs of small- to mid-cap companies, in which we ask them about products in development. Here we talk with Randy Milby, Chief Executive Officer at Hillstream BioPharma, Inc, Chester, New Jersey (https://www.hillstreambio.com).

 RANDY MILBY: I’ll start with how I founded the company, Hillstream Biopharma. Until recently, the end of last September, I was the CEO of CorMedix, which is a publicly traded company on the New York Stock Exchange. While I was at CorMedix, there was a paper that came out of Germany that said that taurolidine combined with vincristine, an anticancer drug, had a synergistic effect on tumors. Taurolidine is a cornerstone antimicrobial compound for CorMedix. It’s not an antibiotic but it has antibacterial effects, and some antifungal effects, and it’s one of the active components of Neutrolin®, which is in a phase 3 study. Neutrolin® is an anti-microbial drug developed as a preventative solution to decrease the threat of infection and blood clots (thrombosis), thereby keeping central venous catheters (CVCs) operating safely and efficiently. (more…)